Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin

Song Xue; Gandhi Pranav; Gilligan Adrienne M.; Arora Prachi; Wang Cheng; Henriques Caroline; Sander Stephen; Smith David M.

首页> 外文期刊>Expert review of pharmacoeconomics & outcomes research >Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin

【24h】

Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin

机译：非瓣膜心房颤动患者（NVAF）患者的全因，中风和流血特异性医疗资源利用的比较，并用Dabigatran或Warfarin新处理

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background: We compared healthcare utilization outcomes and persistence among non-valvular atrial fibrillation (NVAF) patients newly treated with dabigatran or warfarin.

机译：背景：我们将医疗保健利用率和持续存在于用Dabigatran或Warfarin新治疗的非瓣膜心房颤动（NVAF）患者。

著录项

来源
《Expert review of pharmacoeconomics & outcomes research》 |2019年第3期|共10页
作者
Song Xue; Gandhi Pranav; Gilligan Adrienne M.; Arora Prachi; Wang Cheng; Henriques Caroline; Sander Stephen; Smith David M.;
展开▼
作者单位

Dept Truven Hlth Analyt Cambridge MA USA;

Dept Boehringer Ingelheim Pharmaceut Inc Ridgefield CT USA;

Dept Truven Hlth Analyt Cambridge MA USA;

Dept Boehringer Ingelheim Pharmaceut Inc Ridgefield CT USA;

Dept Boehringer Ingelheim Pharmaceut Inc Ridgefield CT USA;

Dept Truven Hlth Analyt Cambridge MA USA;

Dept Boehringer Ingelheim Pharmaceut Inc Ridgefield CT USA;

Dept Truven Hlth Analyt Cambridge MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
Atrial fibrillation; stroke; bleed; oral anticoagulants; NVAF;

机译：心房颤动;中风;出血;口服抗凝剂;NVAF;

相似文献

外文文献
中文文献
专利

1. Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin [J] . Song Xue, Gandhi Pranav, Gilligan Adrienne M., Nature reviews Cancer . 2019,第2期

机译：非瓣膜心房颤动患者（NVAF）患者的全因，中风和流血特异性医疗资源利用的比较，并用Dabigatran或Warfarin新治疗
2. All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin [J] . Adrienne M. Gilligan, Pranav Gandhi, Xue Song, JPC Bulletin on Iron & Steel . 2017,第6期

机译：全原因，中风和流血的医疗费用：使用Dabigatran或Warfarin的非瓣膜心房颤动（NVAF）患者的比较
3. All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin [J] . Adrienne M. Gilligan, Pranav Gandhi, Xue Song, American journal of cardiovascular drugs: drugs, devices, and other interventions . 2017,第6期

机译：全原因，中风和流血的医疗费用：使用Dabigatran或Warfarin的非瓣膜心房颤动（NVAF）患者的比较
4. Epicardial Pulmonary Vein Isolation By Cryoablation As Concomitant Cardiac Surgery To Treat Non-valvular Atrial Fibrillation "Lavie Technique" [C] . H. Kubota, M. Sato, T. Fujiki, World Congress on Cardiac Pacing and Electrophysiology . 2003

机译：心外膜肺静脉隔离通过冷冻剂作为伴随心脏手术治疗非瓣膜心房颤动“Lavie技术”
5. Cost effectiveness of warfarin in anticoagulant clinic after introduction of dabigatran for stroke prevention in atrial fibrillation patients in the United States [D] . Alhazami, Mai S. 2015

机译：在美国引入达比加群后预防心房颤动患者中风后华法林在抗凝临床中的成本效益
6. Treatment Persistence and Discontinuation with Rivaroxaban Dabigatran and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States [O] . Craig I. Coleman, Muralikrishna Tangirala, Thomas Evers -1

机译：在美国非瓣膜性心房颤动患者中使用利伐沙班达比加群和华法林的治疗持久性和停药预防卒中。
7. Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States [O] . Bancroft Tim, Lim Jonathan, Wang Cheng, 2016

机译：在美国新诊断为非瓣膜性房颤并新用达比加群与华法林治疗的患者的医疗保健资源利用，成本和持续性

Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅